Loading...

Lonza Group AG

LONN.SW•SIX
Healthcare
Medical - Diagnostics & Research
CHF564.00
CHF-5.40(-0.95%)

Lonza Group AG (LONN.SW) Stock Overview

Explore Lonza Group AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap38.5B
P/E Ratio62.64
EPS (TTM)$8.90
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Week$564.31
1 Month$565.43
3 Months$634.56
1 Year Target$608.57

LONN.SW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Lonza Group AG (LONN.SW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 50.41, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $608.57.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 62.64 and a market capitalization of 38.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

50.41RSI (14)
-0.88MACD
12.27ADX
Revenue Growth
-2.13%
↓ 2.13%
Profit Growth
CHF9.004
↓ 2.75%
EPS Growth
CHF9.004
↑ 0.56%
Operating Margin
15.27%
↑ 9.55%
ROE
6.81%
↓ 2.75%
Dividend Yield
0.00%
↑ 14.55%
Analyst Recommendations data is not available for LONN.SWAnalyst Recommendations details for LONN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

CEO

Wolfgang Wienand

Employees

17,995

Headquarters

Muenchensteinerstrasse 38, Basel

Founded

1999

Frequently Asked Questions

;